The state will continue to cover GLP-1s prescribed for Type 2 diabetes, cardiovascular disease and sleep apnea. The state has about 40,000 employees, and the policy change is expected to save nearly $17 million annually, according to the report.
Less than half of states provide coverage of GLP-1 drugs for weight loss to state employees, according to data from Leverage and the Robert Wood Johnson Foundation.
Illinois added coverage of the drugs last year for state employees, while North Carolina rescinded coverage.
